Xuchang Ketop Testing Research Ins (003008) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Xuchang Ketop Testing Research Ins ¥15.53, price ¥19.75, upside -21.4%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Xuchang Ketop Testing Research Ins for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥10.33 – ¥26.33 · fair‑value band ¥10.58 – ¥20.93 · the ¥19.75 price screens above the ¥15.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Xuchang Ketop Testing Research Ins in your weekly email
Every Wednesday you see whether Xuchang Ketop Testing Research Ins is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Xuchang KETOP Testing Research Institute Co.,Ltd operates as a third-party testing company in China.
Show more
Xuchang KETOP Testing Research Institute Co.,Ltd operates as a third-party testing company in China. It provides testing services for protection and control equipment, charging and swapping equipment, AC/DC power supply equipment testing, new energy photovoltaic energy storage converter transformer equipment, distribution network terminal equipment, electromagnetic compatibility, environmental and reliability testing, plant simulation modeling testing, software and cybersecurity testing, on-site acceptance testing, testing of monitoring system equipment, online monitoring equipment testing, other types of equipment testing, medical electrical equipment testing, automotive electronic equipment testing, remote sensing equipment testing, intelligent transportation equipment testing, and testing of household appliances. The company was founded in 2005 and is based in Xuchang, China.
Stock analysis
Xuchang Ketop Testing Research Ins (003008) currently trades at ¥19.75, while our model-based Fair Value estimate is ¥15.53, implying the stock looks roughly 27.2% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥16.10 per share, and 1 of the 26 models we run sit above the ¥19.75 price.
Bear case: the Earnings-Based group reads lowest at ¥6.12, and 25 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥10.58 (bear) to ¥20.93 (bull), the price of ¥19.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Industrials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Xuchang Ketop Testing Research Ins reported revenue of 233M CNY in FY2025 versus 144M CNY in FY2021, a compound +12.8%/yr. Reported net income was 88.2M CNY in FY2025, compounding +8.2%/yr from FY2021.
Key figures
Market cap 2.0B CNY (≈ $306M) · P/E ratio 26.0 · P/S ratio 9.85 · EPS (TTM) ¥0.7600 · Dividend yield 5.1% · Net margin 37.9% · Return on equity 7.3% · Return on assets (EBIT) 7.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 0% fair-value upside, at −21%, 003008 screens richer than that median.
Fair Value models
Bear ¥10.58Fair Value ¥15.53Bull ¥20.93
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.6%
Dividend (yield on the price)5.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1% vs −9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.50% → 46%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 2.0%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +6.7% a year for the price.
Compare Xuchang Ketop Testing Research Ins with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Business Services · 248 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside−21% · Below median
Profitability
Return on equity (TTM)7% · Below median
Return on assets5% · Above median
Net margin (TTM)35% · Top 25%
Operating margin (TTM)18% · Top 25%
Growth and dividend
Revenue growth−20% · Bottom 25%
Dividend yield (TTM)5.1% · Above median
Valuation Multiplesvs Specialty Business Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Xuchang Ketop Testing Research Ins Fair Value". https://www.fairvalue-calculator.com/stock/003008
Frequently asked questions
Is Xuchang Ketop Testing Research Ins (003008) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥15.53 versus a price of ¥19.75, about −21% upside (overvalued).
What is the fair value of 003008?
Our model-based fair value for Xuchang Ketop Testing Research Ins is ¥15.53 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥19.75.
What is the quality score of 003008?
Xuchang Ketop Testing Research Ins has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xuchang Ketop Testing Research Ins (003008)?
Our model-based price target is the fair value of ¥15.53 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ¥10.58, optimistic scenario ¥20.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Xuchang Ketop Testing Research Ins stock forecast for 2026?
Our models put fair value at ¥15.53, about −21% upside versus a price of ¥19.75 (overvalued). Cautious scenario ¥10.58, optimistic scenario ¥20.93. The calculation is refreshed regularly with new filings.
What is the revenue of Xuchang Ketop Testing Research Ins (003008)?
Xuchang Ketop Testing Research Ins reported trailing-twelve-month revenue of about 223M CNY (latest available figure, as of Sep 24, 2026).
Does Xuchang Ketop Testing Research Ins pay a dividend?
Xuchang Ketop Testing Research Ins currently shows a dividend yield of about 5.06% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Xuchang Ketop Testing Research Ins (003008)?
For today's price to be fair in a discounted-cash-flow model, Xuchang Ketop Testing Research Ins would have to grow free cash flow by +8.5 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 003008 use?
Our models discount Xuchang Ketop Testing Research Ins at 11.9 %: a base by market capitalisation (micro), damped by beta 0.37, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Xuchang Ketop Testing Research Ins that is +8.5 % per year a year over ten years, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Xuchang Ketop Testing Research Ins (003008) delivered so far?
Over the past 5 years revenue at Xuchang Ketop Testing Research Ins grew +7.1 % a year. The price currently implies +8.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Xuchang Ketop Testing Research Ins (003008) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Xuchang Ketop Testing Research Ins (+8.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Xuchang Ketop Testing Research Ins (003008)?
The free-cash-flow yield on the price is 4.58 %: that much free cash flow Xuchang Ketop Testing Research Ins produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Xuchang Ketop Testing Research Ins (003008)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xuchang Ketop Testing Research Ins it is ¥15.53 per share (as of Sep 24, 2026), against a price of ¥19.75. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Xuchang Ketop Testing Research Ins stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 003008 trades above its calculated fair value: price ¥19.75, fair value ¥15.53, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003008?
No. The price is what the market pays today (¥19.75); the fair value is what the company's own numbers justify (¥15.53). For Xuchang Ketop Testing Research Ins the two are ¥4.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xuchang Ketop Testing Research Ins worth?
The market values Xuchang Ketop Testing Research Ins at about 2.0B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥19.75; our models calculate a fair value of ¥15.53 per share.
What do the bullish and bearish scenarios say about 003008?
Our models span a range for Xuchang Ketop Testing Research Ins: cautious scenario ¥10.58, base ¥15.53, optimistic ¥20.93 per share (as of Sep 24, 2026, price ¥19.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 003008?
Xuchang Ketop Testing Research Ins trades at a price-to-earnings ratio of 26.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥15.53 is built from several models across several years. Other multiples: P/B 1.9, P/S 9.2, EV/EBITDA 13.9.
How solid is the balance sheet of Xuchang Ketop Testing Research Ins (003008)?
Balance-sheet figures for Xuchang Ketop Testing Research Ins (as of Sep 24, 2026): return on equity 7.3%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 003008 from its 52-week high?
Xuchang Ketop Testing Research Ins trades at ¥19.75, about 18% below its 52-week high of ¥24.19 and 23% above the low of ¥16.00 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥15.53 is for.
Which stocks are comparable to Xuchang Ketop Testing Research Ins?
From the same area (Industrials) we also value Cintas Corporation, Thomson Reuters Corporation, Copart, Inc, Global Payments Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xuchang Ketop Testing Research Ins stock attractive at the current price?
The data as of Sep 24, 2026: price ¥19.75, calculated fair value ¥15.53 (−21%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003008 calculated?
We run Xuchang Ketop Testing Research Ins through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥15.53, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Xuchang Ketop Testing Research Ins itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xuchang Ketop Testing Research Ins (003008)?
The closing price on Sep 24, 2026 was ¥19.75. Our model-based fair value is ¥15.53, about −21% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xuchang Ketop Testing Research Ins right now?
A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range (¥10.58 to ¥20.93) leaves room in how you read the outcome.
Key figures of Xuchang Ketop Testing Research Ins
How large is the market capitalisation of Xuchang Ketop Testing Research Ins (003008)?
The market capitalisation of Xuchang Ketop Testing Research Ins is 2.0B CNY (≈ $306M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xuchang Ketop Testing Research Ins (003008)?
The price-to-sales ratio of Xuchang Ketop Testing Research Ins is 9.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xuchang Ketop Testing Research Ins (003008)?
Earnings per share at Xuchang Ketop Testing Research Ins are ¥0.7600 (price ÷ EPS = P/E 26.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Xuchang Ketop Testing Research Ins (003008)?
The dividend yield of Xuchang Ketop Testing Research Ins is 5.1% (payout 132%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Xuchang Ketop Testing Research Ins (003008)?
The net margin of Xuchang Ketop Testing Research Ins is 37.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xuchang Ketop Testing Research Ins (003008)?
The return on equity (ROE) of Xuchang Ketop Testing Research Ins is 7.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xuchang Ketop Testing Research Ins (003008)?
On an EBIT basis the return on assets of Xuchang Ketop Testing Research Ins is 7.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xuchang Ketop Testing Research Ins (003008)?
The operating margin of Xuchang Ketop Testing Research Ins is 18.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xuchang Ketop Testing Research Ins (003008)?
Revenue at Xuchang Ketop Testing Research Ins is growing −19.7% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Xuchang Ketop Testing Research Ins (003008)?
Earnings per share at Xuchang Ketop Testing Research Ins are growing −56.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Xuchang Ketop Testing Research Ins (003008) hold?
Xuchang Ketop Testing Research Ins holds more cash than debt, 93.4M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Xuchang Ketop Testing Research Ins in the live analysis
One click puts Xuchang Ketop Testing Research Ins on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
